Valentis issued third patent for GeneSwitch technology.Valentis, Inc. (Burlingame, CA; 650-697-1900) announced that the United States Patent and Trademark Office The United States Patent and Trademark Office (PTO or USPTO) is an agency in the United States Department of Commerce that provides patent protection to inventors and businesses for their inventions, and trademark registration for product and intellectual property has issued a third patent covering the company's GeneSwitch gene regulation technology. United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. patent 5,935,934 titled, "Mutated Steroid Hormone Receptors, Methods for Their Use and Molecular Switch for Gene Therapy," issued August 10, 1999.
The GeneSwitch technology provides precise control over the level and duration of gene expression when introduced via gene therapy. Using the GeneSwitch, therapeutic genes may be expressed by administration of an orally bioavailable drug in a dose-dependent manner. Levels of a therapeutic protein can be controlled as needed as needed prn. See prn order. by administration of the regulating drug in pill form.
Applications of the GeneSwitch technology include viral and plasmid-based gene therapy, as well as functional genomic studies using transgenic animals. Valentis' patents on the GeneSwitch technology, which also include previously issued United States Patent 5,364,791 and 5,874,534, cover gene regulation using steroid hormone receptors in any gene delivery system and specifically include the regulation of therapeutic genes in the body.
"The strong proprietary position and solid preclinical performance characteristics of the GeneSwitch make it a valuable part of the technology Valentis uses to develop gene therapy products," stated Benjamin F. McGraw, chairman, president and chief executive officer of Valentis. "Certain gene therapies require control over the level and duration of expression of the therapeutic proteins they produce. GeneSwitch gives us the capability to turn the activity of the gene on or off as needed, enhancing the control of gene therapy products."
The functionality of the GeneSwitch technology to regulate long-term gene expression using a plasmid-based system was published in the June 10, 1999 issue of the journal, Human Gene Therapy by Valentis scientists. The paper showed induction of high levels of gene expression in the muscle and secretion of protein in bloodstream after administration of very low doses of an antiprogestin drug. Repetitive regulation of gene expression Gene modulation redirects here. For information on therapeutic regulation of gene expression, see therapeutic gene modulation.
. was achieved for several weeks after a single dose of the GeneSwitch plasmid.
The patent was issued to Baylor College of Medicine Baylor College of Medicine is a private medical school located in Houston, Texas, USA on the grounds of the Texas Medical Center. It has been consistently rated the top medical school in Texas and among the best in the United States. (Houston, TX), to which Valentis has an exclusive license. The GeneSwitch technology was originally developed in the laboratory of Dr. Bert W. O'Malley, MD, chairman of the department of cell biology Cell biology
The study of the activities, functions, properties, and structures of cells. Cells were discovered in the middle of the seventeenth century after the microscope was invented. at Baylor, and a member the Valentis board of directors. The full text of the patent can be found on the Internet at: www.uspto.gov.
Valentis, formed in March 1999 by the merger of GeneMedicine, Inc. and Megabios Corporation, is focused on the development of products incorporating its proprietary biologics delivery systems. The company uses its expertise in gene delivery and expression to create gene medicines that are intended to provide a new approach to the treatment of diseases with high unmet need or where current therapies are inadequate. The company's initial focus has been on the development of gene medicines for treating certain cancers, cardiovascular diseases, neuromuscular neuromuscular /neu·ro·mus·cu·lar/ (-mus´ku-ler) pertaining to nerves and muscles, or to the relationship between them.
1. disorders, and pulmonary diseases, as well as the development of genetic vaccines for the treatment or prevention of infectious diseases infectious diseases: see communicable diseases. . Gene medicines deliver instructions to targeted cells in the body to produce therapeutic proteins.
The company has established corporate partnerships with Hoffman-La Roche (Switzerland), Eli Lilly and Company Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company and one of the world's largest corporations. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States. (Indianapolis, IN; 317-261-2000), Glaxo Wellcome plc (London, United Kingdom) and a manufacturing partnership with DSM 1. DSM - Data Structure Manager.
An object-oriented language by J.E. Rumbaugh and M.E. Loomis of GE, similar to C++. It is used in implementation of CAD/CAE software. DSM is written in DSM and C and produces C as output. Biologics and Qiagen NV.